131 related articles for article (PubMed ID: 23896305)
21. The increasing mortality burden of liver disease among opioid-dependent people: cohort study.
Gibson A; Randall D; Degenhardt L
Addiction; 2011 Dec; 106(12):2186-92. PubMed ID: 21749525
[TBL] [Abstract][Full Text] [Related]
22. Mortality and causes of death among users of methadone maintenance treatment in Israel, 1999-2008.
Rosca P; Haklai Z; Goldberger N; Zohar P; Margolis A; Ponizovsky AM
Drug Alcohol Depend; 2012 Sep; 125(1-2):160-3. PubMed ID: 22483811
[TBL] [Abstract][Full Text] [Related]
23. Prescription opioid abuse based on representative postmortem toxicology.
Häkkinen M; Vuori E; Ojanperä I
Forensic Sci Int; 2014 Dec; 245():121-5. PubMed ID: 25447184
[TBL] [Abstract][Full Text] [Related]
24. Sociodemographic characteristics and drug abuse patterns of treatment-seeking illicit drug abusers in Finland, 1997-2008: the Huuti study.
Onyeka IN; Uosukainen H; Korhonen MJ; Beynon C; Bell JS; Ronkainen K; Föhr J; Tiihonen J; Kauhanen J
J Addict Dis; 2012; 31(4):350-62. PubMed ID: 23244554
[TBL] [Abstract][Full Text] [Related]
25. Acute complications and drug misuse are important causes of death for children and young adults with type 1 diabetes: results from the Yorkshire Register of diabetes in children and young adults.
Feltbower RG; Bodansky HJ; Patterson CC; Parslow RC; Stephenson CR; Reynolds C; McKinney PA
Diabetes Care; 2008 May; 31(5):922-6. PubMed ID: 18285550
[TBL] [Abstract][Full Text] [Related]
26. Patients' help-seeking behaviours for health problems associated with methadone and buprenorphine treatment.
Winstock AR; Lea T; Sheridan J
Drug Alcohol Rev; 2008 Jul; 27(4):393-7. PubMed ID: 18584389
[TBL] [Abstract][Full Text] [Related]
27. Prevalence and clinical relevance of corrected QT interval prolongation during methadone and buprenorphine treatment: a mortality assessment study.
Anchersen K; Clausen T; Gossop M; Hansteen V; Waal H
Addiction; 2009 Jun; 104(6):993-9. PubMed ID: 19392907
[TBL] [Abstract][Full Text] [Related]
28. [High mortality from both natural and unnatural causes. A 10-year follow-up of patients admitted to a center for poisoning treatment after attempted suicide].
Nordentoft M; Breum L; Munck LK; Nordestgaard AG; Hunding A; Bjaeldager PA
Ugeskr Laeger; 1994 Oct; 156(42):6210-5. PubMed ID: 7998360
[TBL] [Abstract][Full Text] [Related]
29. Suicide and other-cause mortality among heroin users in Taiwan: a prospective study.
Lee CT; Chen VC; Tan HK; Chou SY; Wu KH; Chan CH; Gossop M
Addict Behav; 2013 Oct; 38(10):2619-23. PubMed ID: 23851391
[TBL] [Abstract][Full Text] [Related]
30. [Two-year follow-up of an opioid-user cohort treated with high-dose buprenorphine (Subutex)].
Fhima A; Henrion R; Lowenstein W; Charpak Y
Ann Med Interne (Paris); 2001 Apr; 152 Suppl 3():IS26-36. PubMed ID: 11435992
[TBL] [Abstract][Full Text] [Related]
31. The prevalence of childhood trauma among those seeking buprenorphine treatment.
Sansone RA; Whitecar P; Wiederman MW
J Addict Dis; 2009; 28(1):64-7. PubMed ID: 19197597
[TBL] [Abstract][Full Text] [Related]
32. High buprenorphine-related mortality is persistent in Finland.
Kriikku P; Häkkinen M; Ojanperä I
Forensic Sci Int; 2018 Oct; 291():76-82. PubMed ID: 30170272
[TBL] [Abstract][Full Text] [Related]
33. Mortality and causes of death among drugged drivers.
Karjalainen K; Lintonen T; Impinen A; Mäkelä P; Rahkonen O; Lillsunde P; Ostamo A
J Epidemiol Community Health; 2010 Jun; 64(6):506-12. PubMed ID: 19897469
[TBL] [Abstract][Full Text] [Related]
34. Excess mortality of suicide attempters.
Ostamo A; Lönnqvist J
Soc Psychiatry Psychiatr Epidemiol; 2001 Jan; 36(1):29-35. PubMed ID: 11320805
[TBL] [Abstract][Full Text] [Related]
35. Mortality among a national population sentenced to compulsory care for substance use disorders in Sweden: descriptive study.
Hall T; Chassler D; Blom B; Grahn R; Blom-Nilsson M; Sullivan L; Lundgren L
Eval Program Plann; 2015 Apr; 49():153-62. PubMed ID: 25577663
[TBL] [Abstract][Full Text] [Related]
36. Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment.
Bell J; Trinh L; Butler B; Randall D; Rubin G
Addiction; 2009 Jul; 104(7):1193-200. PubMed ID: 19563562
[TBL] [Abstract][Full Text] [Related]
37. Fatal overdoses and deaths by other causes in a cohort of Norwegian drug abusers--a competing risk approach.
Ødegård E; Amundsen EJ; Kielland KB
Drug Alcohol Depend; 2007 Jul; 89(2-3):176-82. PubMed ID: 17240086
[TBL] [Abstract][Full Text] [Related]
38. Potential Years of Life Lost Due to Premature Mortality Among Treatment-Seeking Illicit Drug Users in Finland.
Onyeka IN; Beynon CM; Vohlonen I; Tiihonen J; Föhr J; Ronkainen K; Kauhanen J
J Community Health; 2015 Dec; 40(6):1099-106. PubMed ID: 25967278
[TBL] [Abstract][Full Text] [Related]
39. Methods and motivations for buprenorphine diversion from public opioid substitution treatment clinics.
Winstock AR; Lea T; Jackson AP
J Addict Dis; 2009; 28(1):57-63. PubMed ID: 19197596
[TBL] [Abstract][Full Text] [Related]
40. Death and suicide among former child and adolescent psychiatric patients.
Engqvist U; Rydelius PA
BMC Psychiatry; 2006 Nov; 6():51. PubMed ID: 17081290
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
